Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development
- Monday, March 1, 2021, 7:00
- Finance
- Add a comment
SUZHOU, China, March 1, 2021 /PRNewswire/ — Suzhou Medilink Therapeutics Ltd. (Medilink), a global biotech company focusing on next-generation antibody-drug conjugate Research & development, announced the closing of a $50 million series A financing, to accelerate its innovative pipeline…
About the Author
adminasapcorp has written 41268 stories on this site.